Skip to main content
. 2012 Jan 10;17(1):15–25. doi: 10.1634/theoncologist.2011-0249

Figure 3.

Figure 3.

Waterfall plot of maximum percentage reduction in target lesions with capecitabine and oxaliplatin (XELOX) plus bevacizumab (n = 220) (A) and with single-agent bevacizumab (n = 210) (B) following six cycles of XELOX plus bevacizumab.

Abbreviations: CR, complete response; PD, progressive disease; PR, partial response; SD, stable disease; XELOX, capecitabine plus oxaliplatin.